Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2019 Jan;20(1):57–73. doi: 10.1016/S1470-2045(18)30687-9

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© 2019 The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY 4.0 license

This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).

PMC Copyright notice

Subgroup analysis of progression-free survival

(A) Forest plot of progression-free survival in the intention-to-treat population. For the response before maintenance (NC or PD) subgroup, the Cox model was inestimable because of the small numbers of patients and events in the subgroup. Comparisons by sex, International Staging System disease stage, and response before maintenance were done as post-hoc analyses. The test for heterogeneity in the Response before maintenance setting only applied to the CR or VGPR and PR or MR subgroups. (B) Kaplan-Meier plot of progression-free survival in transplantation-eligible patients. (C) Kaplan-Meier plot of progression-free survival in transplantation-ineligible patients. CR=complete response. CRD=cyclophosphamide, lenalidomide, and dexamethasone. CTD=cyclophosphamide, thalidomide, and dexamethasone. CVD=cyclophosphamide, bortezomib, and dexamethasone. HR=hazard ratio. KCRD=carfilzomib, cyclophosphamide, lenalidomide, and dexamethasone. MR=minimal response. NC=no change. PD=progressive disease. PR=partial response. VGPR=very good partial response. *Likelihood ratio test for heterogeneity of effect among patients with subgroup data available.

Subgroup analysis of progression-free survival

(A) Forest plot of progression-free survival in the intention-to-treat population. For the response before maintenance (NC or PD) subgroup, the Cox model was inestimable because of the small numbers of patients and events in the subgroup. Comparisons by sex, International Staging System disease stage, and response before maintenance were done as post-hoc analyses. The test for heterogeneity in the Response before maintenance setting only applied to the CR or VGPR and PR or MR subgroups. (B) Kaplan-Meier plot of progression-free survival in transplantation-eligible patients. (C) Kaplan-Meier plot of progression-free survival in transplantation-ineligible patients. CR=complete response. CRD=cyclophosphamide, lenalidomide, and dexamethasone. CTD=cyclophosphamide, thalidomide, and dexamethasone. CVD=cyclophosphamide, bortezomib, and dexamethasone. HR=hazard ratio. KCRD=carfilzomib, cyclophosphamide, lenalidomide, and dexamethasone. MR=minimal response. NC=no change. PD=progressive disease. PR=partial response. VGPR=very good partial response. *Likelihood ratio test for heterogeneity of effect among patients with subgroup data available.